Opinion|Videos|May 12, 2026
Safety and Tolerability of Zongertinib in HER2-Positive NSCLC
Author(s)Joshua K. Sabari, MD
New data show zongertinib is well tolerated in frontline lung cancer, with manageable diarrhea, minimal rash, and low ILD risk.
Advertisement
Episodes in this series
Joshua K. Sabari, MD, highlights the safety and tolerability of the HER2-selective TKI zongertinib in patients with HER2 mutation–positive non–small cell lung cancer, as observed in the Beamion LUNG‑1 trial. He specifically covers the incidence and management of diarrhea and rash. Sabari also compares the safety and tolerability of zongertinib vs other agents used in this setting.
Advertisement
Related to this article
FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus bendamustine-rituximab.
Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.
Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.
Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.
The MUC16xCD3 bispecific antibody showed a 73% response rate in phase 1/2 trial; the sponsor announced plans for a potential registrational cohort and phase 3 trial.
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
2
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
3
What Stood Out at IMS 2026? Five Myeloma Experts Weigh In
4
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
5